Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- (-) Biopharmaceutical Innovation
- Bundled Payments
- (-) Clinical Pathways
- (-) Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- (-) Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- (-) Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- (-) Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Audience
Display Only
Showing 78 Results
The President’s victory lap on the success of price controls is premature
In a commentary published in the Sarasota Herald-Tribune, NPC's John M. O’Brien discusses the potential effects of new price controls and what the future holds for Medicare.
Innovating to Help Patients with Rare Diseases
One out of every 10 Americans live with a rare disease. Rare Disease Day serves as a reminder of their many needs and challenges and the work that researchers, clinicians, and our member companies do…
Shared Decision-Making Makes Sense for Patients and the Bottom Line
If shared decision-making is good for patients, is it good for the bottom line as well? A new study from NPC and Real Chemistry sheds light.
Good Health Policy Requires High-Quality Evidence
In health policy debates, honest, realistic and evidence-based discussions are foundational.
An Oversimplified Drug Price Policy That Misses the Point
Drug price controls have a range of downstream consequences for the biopharmaceutical market and, more importantly, for patients.
The Impact of Price Regulation on Innovation: What the Research Shows
Potential drug price controls have a range of downstream consequences for the biopharmaceutical market and, more importantly, for patients.
Predictors of Adherence to Oral Anticancer Medications: The Impact of Out-of-Pocket Costs
Biopharmaceutical innovation has led to an increase in the availability of oral anticancer medications (OAMs), but research shows that almost half of patients on OAMs do not take their medications as…
NPC’s John O’Brien Discusses March-in, Co-pays, and Patient Access
On a recent episode of VITAL HEALTH podcast, John M. O’Brien discusses the health care ecosystem and the importance of fostering biopharmaceutical innovation and improving patient access.
Bringing the Patient Voice Into Benefit Design
Diverse populations have diverse needs, and that's why NPC Chairman Steven Romano says benefit design and coverage policies should start with the patient in mind.
Wage and Its Impact on Access and Adherence to Specialty Medications
Research found that lower-wage employees faced higher out-of-pocket costs, were less likely to use specialty medicines than higher-income workers and relied more regularly on emergency room care. …
Innovation Matters: Changing Lives for Cystic Fibrosis Patients
In this video from NPC’s Innovation Matters series, cystic fibrosis patient advocate Katherine Fielding discusses how the invention of modulator therapies has changed her life and how more innovation…
NPC’s John O’Brien Discusses The Myth of Average on AiArthritis Voices 360 Talk Show
On a recent episode of AiArthritis Voices 360 Podcast, John M. O’Brien discusses NPC’s research on the importance of fostering biopharmaceutical innovation and improving patient access to the right…
Continuing Innovation for Rare Conditions Under the Orphan Drug Act
The Orphan Drug Act has served as a catalyst for the development of many innovative therapies to treat rare diseases. Without the appropriate incentives to develop therapies for rare or ultra-rare…
Innovation Matters: Revolutionary Changes for Arthritis Patients
Anna Hyde, vice president of advocacy and access for the Arthritis Foundation, discusses how biopharmaceutical innovation has advanced the health of people living with arthritis.
Innovation Matters: The Evolution of Cancer Therapies
In this video from NPC’s Innovation Matters series, Dr. Peter Emtage describes the evolution of cancer therapies and the importance of ensuring patient access to these medicines.
Addressing the Needs of People Living With Autoimmune Disorders: A Conversation With Molly Murray
NPC had the opportunity to speak with Molly Murray, president and CEO of the Autoimmune Association, to learn more about the importance of understanding how individual patient differences affect the…
Innovation Matters: The Unintended Consequences of Drug Pricing Regulation
In NPC’s Innovation Matters video series, hear from patient advocates, researchers, and other stakeholders about the potential unintended consequences for patient health if drug pricing policies harm…
Innovation Matters: Building a Healthier World
In NPC’s new Innovation Matters video series, patient advocates, researchers, and other stakeholders talk about the importance of biopharmaceutical innovation for patient health.
What If Groundbreaking Medicines Never Existed?
New research from estimates what health gains might have been lost without the introduction of influential innovations for six serious diseases.
Why Patients Are Paying More at the Pharmacy Counter in Early 2022 - And What We Can Do to Fix It
NPC Immediate Past Board Chair Mike Ryan and CSO Sharon Phares explore policy solutions to ensure patients can have predictable and affordable out-of-pocket costs for medicines.